| Title |
11C-Choline PET/CT and PSA kinetics
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, April 2013
|
| DOI | 10.1007/s00259-013-2377-z |
| Pubmed ID | |
| Authors |
Paolo Castellucci, Maria Picchio |
| Abstract |
The role of PET/CT with radiolabelled (18)F-choline or (11)C-choline in patients with prostate cancer after primary treatment has not been established yet and there are no guidelines on the appropriate use of this emerging modality. According to the literature, choline PET/CT may have a role in restaging the disease in patients with biochemical relapse for the detection of local and/or lymph node and/or distant recurrence. The aim of this brief review is to summarize the results of the most relevant published studies with particular focus on the relationship between prostate-specific antigen levels and kinetics and the sensitivity of choline PET/CT for optimizing the selection of patients who may benefit the most from this diagnostic procedure, especially early after biochemical recurrence. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 37 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 23% |
| Student > Master | 6 | 15% |
| Student > Bachelor | 5 | 13% |
| Other | 5 | 13% |
| Professor > Associate Professor | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 7 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 51% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Computer Science | 2 | 5% |
| Nursing and Health Professions | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 April 2013.
All research outputs
#21,153,429
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#2,610
of 3,083 outputs
Outputs of similar age
#175,934
of 200,708 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#21
of 36 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 200,708 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.